- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
Chapter 2
Genetics and Diabetic Retinopathy
David G. Telander, Kent W. Small, and David J. Browning
Diabetic retinopathy (DR) is the leading cause of new cases of blindness for people between 20 and 64 years of age in the United States. While glycemic control is the chief risk factor for development and progression of diabetic retinopathy, there is increasing evidence for heritable risk factors. An increasing number of genetic linkage studies have uncovered the role that several genes have in the development and progression of DR.
Unlike sickle cell anemia or Huntington’s disease, diabetes mellitus does not demonstrate a mendelian inheritance pattern. No single gene causes diabetes. Rather, it is a complex genetic disease with interaction among genes and the environment. The alleles, or forms of genes, that are associated with complex genetic diseases such as diabetes are often common variants. Rather than being causative, these alleles contribute to the risk of disease expression affecting severity and age of onset.1 Diabetic retinopathy can be considered as a complex trait as well and may have a constellation of susceptibility and protective genes distinct from those associated with diabetes mellitus. There are many levels to the complexity of the interaction of these genes and gene products. For example, hemoglobin A1c (HbA1c) levels have a genetically determined component in type 1 diabetes that is independent of blood glucose level and are in turn associated with rates of progression of retinopathy.2
Non-genetic risk factors for diabetic retinopathy are well known, including duration of diabetes, glycemic control, and hypertension; however, the
D.G. Telander (*)
Davis Medical Center, University of California, Sacramento, CA 95817, USA
e-mail: dgtelander@ucdavis.edu
genetic risk factors for development and progression of diabetic retinopathy are only beginning to be understood.3,4 A greater than expected prevalence of diabetic retinopathy exists in siblings with diabetic retinopathy than in non-siblings.5 Differences in frequency of the disease among different ethnicities and populations also suggest a genetic component contributing to diabetic retinopathy.6,7 Differences in relative prevalence of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) in different racial groups further suggest that components of diabetic retinopathy have independent genetic susceptibility profiles.8 Within a given population, the marked variation in onset and severity of retinopathy that cannot be explained by known risk factors indicates genetic susceptibility to DR.9 For example, in African-American type 1 diabetics, clinical risk factors could account for only 27% of the variance in DR severity.10 Because of difficulties unraveling the effects of shared environment from shared genes in family studies, these epidemiologic studies provide suggestive evidence only.7 Nevertheless, such evidence is an important precursor to molecular genetic explorations searching for specific genetic associations.7
2.1 Background for Clinical Genetics
This section is a brief review of genetic concepts for understanding the relevant literature and associated terminology. Lack of familiarity of genetic concepts by clinicians has often been identified as an obstacle in progress toward understanding disease pathogenesis.11 Our intent in this chapter is to help bridge this obstacle.
D.J. Browning (ed.), Diabetic Retinopathy, DOI 10.1007/978-0-387-85900-2_2, |
31 |
Springer ScienceþBusiness Media, LLC 2010 |
|
32 |
D.G. Telander et al. |
|
|
Understanding of molecular genetics begins with the study of deoxyribonucleic acid (DNA), a linear polymer comprised of two strands containing sequences of four nitrogen-containing bases – adenine (A), guanine (G), thymine (T), and cytosine (C) (Fig. 2.1).
Fig. 2.1 Each strand of DNA consists of a backbone of deoxyribose phosphate sugars with attached purine and pyrimidine bases. The bases show complementarity by forming hydrogen bonds with paired bases in the fellow strand. Adapted with permission from Della12
DNA is the template for its own replication. DNA also serves as a template for the creation of ribonucleic acid (RNA) in a process called transcription. This RNA copy of the DNA then in turn serves as the template for synthesis of proteins. In transcription, DNA is always read beginning at the 50 end and proceeding to the 30 end. The two strands of a DNA molecule are held together by hydrogen bonds between paired bases. Adenine in one strand always binds to thymine in its fellow strand and likewise for cytosine and guanine. For example, if a section of the sequence of one strand is 50-ATGAC-30, then its fellow strand at this locus reads 30-TACTG-50. Binding of complementary strands of DNA or between a single strand of DNA and its complementary RNA strand is termed hybridization.13
The central dogma of molecular biology states that DNA is transcribed to an RNA which is in turn translated into protein (Fig. 2.2). In the cell nucleus, transcription of DNA occurs first as a messenger RNA precursor (mRNA) that contains
the transcript of the protein-coding DNA sequence (exons), the non-protein-coding DNA sequence (introns), and untranslated regions adjacent to the 30 and 50 termini. The transcribed introns are spliced out to yield a mature mRNA product (Fig. 2.2). In the cell cytoplasm, mature mRNA is translated as three base segments called codons into amino acids that compose the protein product of the gene.14 This intricate process of an RNA-guided protein synthesis is called translation.
Humans have 23 pairs of chromosomes, each comprised of DNA and associated proteins. Each chromosome contains many genes, or sequences of DNA that code for proteins, as well as sequences of DNA dedicated to regulatory functions such as initiating transcription or translation. There are 3.3 billion base pairs in the human genome.1 The latest estimates on the number of genes in the human genome are 20,000–25,000.15 Ninety-nine percent of the genome does not code for proteins.16 These noncoding sections of the genome are broken into classes called introns and intergenic DNA. Introns, comprising 24% of the human genome, are segments of DNA adjacent to exons that are initially transcribed into an RNA strand but are then excised from initial RNA transcripts before the final mRNA strand leaves the nucleus for the cytoplasm on the way to protein synthesis (Fig. 2.2). Intergenic DNA, comprising 75% of the genome, remains untranscribed and has unknown func-
tion.16 The remaining 1% of DNA composes the exons that code for proteins.16,17
2.2The Role of Polymorphisms in Genetic Studies
The DNA sequences of any two human beings are 99% identical. The 1% of DNA that differs between any two individuals constitutes the genetic basis of certain diseases. In addition, factors that control the expression of the genes contribute to different phenotypes including disease. The purpose of genetic investigations is to determine which genes contribute to disease. On average, a difference in DNA sequence between two persons is found once per 1,200 base pairs. When a variation of the genetic locus is found in at least 1% of a given human population, the variation is termed as polymorphism.
2 Genetics and Diabetic Retinopathy |
33 |
|
|
Fig. 2.2 DNA is transcribed into an mRNA precursor which is refined to mature mRNA by the excision of sequences corresponding to introns and transported out of the nucleus
into the cytoplasm. Translation of mature mRNA results in a protein product. Adapted with permission from Della12
There are several categories of polymorphisms. Single nucleotide polymorphisms (SNPs) are single substitutions of one base for another at a certain position. There are many variations in
nomenclature for these, but one common way of naming an SNP is exemplified by c.74C>G. This means that at the level of the coding DNA sequence (indicated by the c. prefix), at position 74, a cytosine
34 |
D.G. Telander et al. |
|
|
is replaced by a guanine. The first letter characterizes the normal base and the second letter following the arrowhead signifies the mutant base. To add to the perplexing nature of the nomenclature, some authors refer to mutations not at the level of the coding DNA, but rather at the level of the altered amino acid sequence in the protein product of the mutant gene. In using this nomenclature, the convention is to list the normal amino acid first followed by the codon number in the sequence of the protein followed by the mutant amino acid. Thus, for example, Ala276Glu means that at codon 276 one finds glutamine replacing the normally expected alanine.18
Another important class of polymorphisms is that of short tandem repeats (STRs) or microsatellites. These are strings of repetitive base pair sequences that vary in length between persons. Thus the alleles are variations in the number of
repeats. For example, at a given location, one might find that one person shows CACA [or (CA)2], the next CACACA [or(CA)3], the next CACACACA [or (CA)4], and so on. Nucleotides are repeated in tandem a number of times. SNPs and STRs are scattered at different locations across the human genome, and encyclopedias of such polymorphisms have been compiled. They provide a fine toothed comb such that any part of the human genome can be probed by selecting an SNP or STR located nearby in the genetic map.
Yet another type of polymorphism, more often used in older genetic association studies, is the restriction fragment length polymorphism. Enzymes called restriction endonucleases cleave DNA at sites where certain DNA sequences are detected. There are many restriction endonucleases (Fig. 2.3). By analyzing the length of fragments of
Fig. 2.3 (a) Restriction enzymes cleave DNA at specific sites. There are many restriction enzymes. Four (MspI, TaqI, EcoRI, and HindIII) are illustrated here as well as the loci cleaved by them. (b) The result of applying a restriction
endonuclease to DNA is a set of DNA fragments that can be separated by electrophoresis. The electrophoretic pattern can distinguish different alleles (A and a). Adapted with permission from Musarella19
